Search
Clesrovimab
go.drugbank.com/drugs/DB18877Approvedto provide passive immunization against RSV infection as an alternative means of protection. … [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233]
Trastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalThe FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. … Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.
CNS-5161
go.drugbank.com/drugs/DB05824ExperimentalCNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.
Edotreotide gallium Ga-68
go.drugbank.com/drugs/DB15494Approved[A185852] Dotatate gallium Ga-68 has lower tumor uptake but this data is highly variable between patients.[A185852] Edotreotide gallium Ga-68 was granted FDA approval on 21 August 2019.[L8597]
Rindopepimut
go.drugbank.com/drugs/DB05374InvestigationalRindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant ...
Ensitrelvir
go.drugbank.com/drugs/DB18834ApprovedInvestigationalEnsitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).
Zuranolone
go.drugbank.com/drugs/DB15490ApprovedInvestigationalThis approval was based on favorable results from 2 phase 3 clinical trials.[L47691] … Zuranolone is a neuroactive steroid that acts as a positive allosteric modulator of the GABA<sub>A</sub> receptors.
Amrubicin
go.drugbank.com/drugs/DB06263InvestigationalIn 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. … Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer
Ibudilast
go.drugbank.com/drugs/DB05266Investigational(codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan.
International brands: Ke TasNemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigational[A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169]